抗肺癌新药透过血脑屏障的研究进展

Progress in the Study of Penetration into Blood-brain Barrier of New Anti-lung Cancer Drugs

肺癌脑转移的发病率逐年上升,血脑屏障被认为是阻碍化疗成功治疗脑转移的重要原因。但近年来的研究证实,脑转移后血脑屏障的完整性被破坏。本文综述了20世纪90年代以来的抗肺癌新药紫衫醇(paclitaxel)、吉西他滨(gemcitabine)、长春瑞滨(vinorelbine)、伊立替康(CPT—11)、托泊替康(topotecan)、替莫唑胺(temozolomide)。吉非替尼(gefitinib)等透过血脑屏障的药代动力学及临床研究进展。其中,topotecan、temozolomide显示了很好的血脑屏障通透性及治疗作用。由于更有效的抗肺癌新药的出现,化疗在肺癌脑转移的治疗中将发挥更积极的作用。

The brain metastases of lung cancer are increasing.The blood-brain harrier(BBB)was consid- ered to be the major hindrance to the successful chemotherapeutic treatment of brain metastases.However,the re- cent studies have demonstrated a break down of the BBB in large area of the tumor vasculature.In this paper,the penetration of new anti-lung cancer drugs into BBB and the use of chemotherapy in brain metastases from lung can- cer are reviewed.With the development of new anti-lung cancer drugs,chemotherapy should become an indispens- able part of treatment for brain metastases of lung cancer.